Botulinum Toxin for Hypertrophy

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Henry Ford Health System, Detroit, MI
Hypertrophy+3 More
Botulinum Toxin - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

This trial will test whether a new medication can reduce scarring compared to using no medication. The study will use two biopsy sites on each person, so that each person serves as their own control. The study hypothesis is that the new medication will lead to less scarring. Botulinum Toxin is used to treat Hypertrophy. Botulinum Toxin has been previously approved by the FDA to treat a different condition.

Eligible Conditions

  • Scarring
  • Hypertrophy

Treatment Effectiveness

Effectiveness Progress

1 of 3

Study Objectives

1 Primary · 0 Secondary · Reporting Duration: 6 months

6 months
Measure

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Trial Design

2 Treatment Groups

Experimental
1 of 2
Placebo
1 of 2
Experimental Treatment
Non-Treatment Group

12 Total Participants · 2 Treatment Groups

Primary Treatment: Botulinum Toxin · Has Placebo Group · Phase 2 & 3

Experimental
Drug
Experimental Group · 1 Intervention: Botulinum Toxin · Intervention Types: Drug
Placebo
Drug
PlaceboComparator Group · 1 Intervention: Normal saline · Intervention Types: Drug
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Botulinum Toxin
2014
Completed Phase 4
~150

Trial Logistics

Trial Timeline

Approximate Timeline
Screening: ~3 weeks
Treatment: Varies
Reporting: 6 months
Closest Location: Henry Ford Health System · Detroit, MI
Photo of henry ford health system 1Photo of henry ford health system 2Photo of henry ford health system 3
2011First Recorded Clinical Trial
1 TrialsResearching Hypertrophy
438 CompletedClinical Trials

Who is running the clinical trial?

Henry Ford Health SystemLead Sponsor
257 Previous Clinical Trials
2,011,163 Total Patients Enrolled
1 Trials studying Hypertrophy
David Ozog, MDPrincipal InvestigatorHenry Ford Health Systems
3 Previous Clinical Trials
52 Total Patients Enrolled

Eligibility Criteria

Age 18+ · All Participants · 1 Total Inclusion Criteria

Mark “yes” if the following statements are true for you:

About The Reviewer

Michael Gill preview

Michael Gill - B. Sc.

First Published: October 9th, 2021

Last Reviewed: August 12th, 2022

Michael Gill holds a Bachelors of Science in Integrated Science and Mathematics from McMaster University. During his degree he devoted considerable time modeling the pharmacodynamics of promising drug candidates. Since then, he has leveraged this knowledge of the investigational new drug ecosystem to help his father navigate clinical trials for multiple myeloma, an experience which prompted him to co-found Power Life Sciences: a company that helps patients access randomized controlled trials.

References